Why Glaukos Doubters Were Wrong Before A 169% Gain

Glaukos spent the past year releasing upbeat trial readouts and record quarterly results, yet the real shock showed up in the portfolio line. For Glaukos shareholders, the return over the past year was 169.0%, including dividends. If you had bought on 5 November 2025, facing clashing analyst views and reimbursement worries, how much of that surge was really foreshadowed by what was already on the record?

Glaukos is not the only name tied to this theme. Zero in on 34 healthcare AI stocks and compare how each one is priced.

The Two Glaukos Stories Investors Actually Faced

The shares cost US$84.35 at the start of the period, so anyone looking at Glaukos then had to decide which story felt more believable.

On the optimistic side, the bullish Narrative argued for a Fair Value of US$123. This served as a rough guide to what the stock might be worth if its assumptions played out, built on iDose TR adoption and a broad glaucoma and corneal pipeline that could support multi year revenue expansion.

The bearish view pointed to a Fair Value of US$74.28 and focused on reimbursement cuts and heavier competition as real threats to pricing, market share, and future profitability.

What The Results Changed For Glaukos

Glaukos reported Q3 2026 revenue of US$211.03 million versus US$133.54 million a year earlier, and net income moved from a loss of US$16.23 million to a profit of US$2.02 million as net margin shifted from 12.2% negative to 1.0% positive. That combination supported the optimistic case on growth, but the thin profitability meant the bullish margin story was only partly tested.

The lesson is simple. When a growth pitch leans on future earnings power, track the net margin line and not just the sales number, then ask whether early profit ratios are moving toward the story that was sold to you.

What Glaukos Buyers Are Paying For Now

Glaukos now trades at US$220 after a 169.0% gain over the past year. The selected Narrative views its Fair Value as below that level, arguing that the current quote already bakes in continued strong commercial execution.

The core bet is that high gross margins eventually turn into reliable cash generation. The question is how reimbursement hurdles, heavier spending and pipeline costs might test that assumption over time.

"Although the company emphasizes high gross margins from iDose TR and Epioxa, the forecast increase in 2026 operating expenses to about US$600 million as it “adds fuel” to commercial investments creates a risk that incremental sales from interventional glaucoma and keratoconus therapies do not fully offset spending."

Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there

Glaukos And The Payer Puzzle

Glaukos depends on getting paid fairly for complex eye procedures. Your returns ultimately hinge on that reimbursement reality.

Step back one layer and you reach insurers and benefit managers setting plan designs and authorizing care.

One large operator in that world is pushing value-based programs, home visits and digital tools that try to keep high risk patients stable.

It is also leaning on AI to strip cost from claims handling and back office work.

If those efforts reshape how care is priced and approved, Glaukos holders may want that playbook on their radar too.

The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 22% above its price

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com